Re-evaluating Our Knowledge of Health System Resilience During COVID-19: Lessons From the First Two Years of the Pandemic.


Journal

International journal of health policy and management
ISSN: 2322-5939
Titre abrégé: Int J Health Policy Manag
Pays: Iran
ID NLM: 101619905

Informations de publication

Date de publication:
2023
Historique:
received: 28 07 2021
accepted: 12 11 2022
medline: 16 8 2023
pubmed: 14 8 2023
entrez: 14 8 2023
Statut: ppublish

Résumé

Health challenges like coronavirus disease 2019 (COVID-19) are becoming increasingly complex, transnational, and unpredictable. Studying health system responses to the COVID-19 pandemic is an opportunity to enhance our understanding of health system resilience and establish a clearer link between theoretical concepts and practical ideas on how to build resilience. This narrative literature review aims to address four questions using a health system resilience framework: ( There is good understanding around information sharing, flexibility and good leadership, learning, maintaining essential services, and the need for legitimate, interdependent systems. Decision-making, localized trust, influences on interdependence, and transformation remain uncertain. Vertical interdependence, monitoring risks beyond the health system, and consequences of changes on the system were not discussed. Teamwork, actor legitimacy, values, inclusivity, trans-sectoral resilience, and the role of the private sector are identified as lessons from COVID-19 that should be further explored for health system resilience. Knowledge of health system resilience has continued to cohere following the pandemic. The eventual consequences of system changes and the resilience of subsystems are underexplored. Through governance, the concept of health system resilience can be linked to wider issues raised by the pandemic, like inclusivity. Our findings show the utility of resilience theory for strengthening health systems for crises and the benefit of continuing to refine existing resilience theory.

Sections du résumé

BACKGROUND
Health challenges like coronavirus disease 2019 (COVID-19) are becoming increasingly complex, transnational, and unpredictable. Studying health system responses to the COVID-19 pandemic is an opportunity to enhance our understanding of health system resilience and establish a clearer link between theoretical concepts and practical ideas on how to build resilience.
METHODS
This narrative literature review aims to address four questions using a health system resilience framework: (
RESULTS
There is good understanding around information sharing, flexibility and good leadership, learning, maintaining essential services, and the need for legitimate, interdependent systems. Decision-making, localized trust, influences on interdependence, and transformation remain uncertain. Vertical interdependence, monitoring risks beyond the health system, and consequences of changes on the system were not discussed. Teamwork, actor legitimacy, values, inclusivity, trans-sectoral resilience, and the role of the private sector are identified as lessons from COVID-19 that should be further explored for health system resilience.
CONCLUSION
Knowledge of health system resilience has continued to cohere following the pandemic. The eventual consequences of system changes and the resilience of subsystems are underexplored. Through governance, the concept of health system resilience can be linked to wider issues raised by the pandemic, like inclusivity. Our findings show the utility of resilience theory for strengthening health systems for crises and the benefit of continuing to refine existing resilience theory.

Identifiants

pubmed: 37579465
doi: 10.34172/ijhpm.2022.6659
pii: 6659
pmc: PMC10125099
doi:
pii:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6659

Informations de copyright

© 2023 The Author(s); Published by Kerman University of Medical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Références

Healthc Policy. 2021 Nov;17(2):54-71
pubmed: 34895410
Int J Environ Res Public Health. 2022 Jan 19;19(3):
pubmed: 35162115
Healthcare (Basel). 2021 Nov 30;9(12):
pubmed: 34946385
Int J Health Policy Manag. 2022 Sep 1;11(9):1682-1694
pubmed: 34273936
J Soc Econ Dev. 2021;23(Suppl 2):290-300
pubmed: 34720480
Health Res Policy Syst. 2020 Dec 18;18(1):136
pubmed: 33339524
PLoS One. 2022 Feb 7;17(2):e0261904
pubmed: 35130289
Health Policy Plan. 2018 Apr 1;33(3):355-367
pubmed: 29325025
World J Surg. 2020 Aug;44(8):2451-2457
pubmed: 32488665
Int J Health Plann Manage. 2022 Jul;37(4):2032-2048
pubmed: 35194831
Lancet Reg Health Eur. 2021 Oct;9:100213
pubmed: 34661187
Popul Health Manag. 2021 Apr;24(2):174-181
pubmed: 33373536
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32792411
Clin Microbiol Infect. 2020 Jun;26(6):669-672
pubmed: 32278082
J Interprof Care. 2021 Nov-Dec;35(6):809-812
pubmed: 34641753
World Dev. 2020 Dec;136:105106
pubmed: 32834387
Environ Res. 2022 Jan;203:111678
pubmed: 34280421
BMJ Glob Health. 2020 Oct;5(10):
pubmed: 33122298
Front Public Health. 2016 Oct 10;4:222
pubmed: 27777926
Front Vet Sci. 2020 Oct 30;7:578649
pubmed: 33195585
BMJ Glob Health. 2021 May;6(5):
pubmed: 33947707
Int J Health Policy Manag. 2017 Apr 04;6(8):431-435
pubmed: 28812842
BMJ. 2021 Dec 8;375:n3043
pubmed: 34880001
Health Policy Plan. 2021 Mar 3;36(1):134-135
pubmed: 33319220
Am J Trop Med Hyg. 2020 Aug;103(2):590-592
pubmed: 32524961
Int J Health Serv. 2020 Jul;50(3):264-270
pubmed: 32517569
Int J Qual Health Care. 2021 Feb 20;33(1):
pubmed: 33313859
Health Econ Policy Law. 2022 Apr;17(2):212-219
pubmed: 32883395
Int J Qual Health Care. 2021 Mar 5;33(1):
pubmed: 32472140
Lancet Reg Health Eur. 2021 Oct 07;9:100216
pubmed: 34693390
Health Policy Plan. 2017 Nov 1;32(suppl_3):iii91-iii94
pubmed: 29149319
WHO South East Asia J Public Health. 2021 Jan-Jun;10(1):2-4
pubmed: 35046150
Health Policy Plan. 2012 Aug;27(5):438-46
pubmed: 21840934
Int J Health Policy Manag. 2022 Sep 1;11(9):1949-1952
pubmed: 35247939
Lancet. 2015 May 9;385(9980):1910-2
pubmed: 25987159
Int J Health Policy Manag. 2022 Sep 1;11(9):1945-1948
pubmed: 35174679
Indian J Med Ethics. 2020 Apr-Jun;V(2):1-4
pubmed: 32393458
Nat Food. 2021 Feb;2(2):68-70
pubmed: 37117413
Health Aff (Millwood). 2021 Feb;40(2):204-211
pubmed: 33476187
BMJ. 2017 May 23;357:j2323
pubmed: 28536191
Front Public Health. 2020 Sep 25;8:508
pubmed: 33102414
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32938609
Int J Health Serv. 2020 Jul;50(3):276-277
pubmed: 32188308
Asia Pac J Public Health. 2021 Jan;33(1):164-165
pubmed: 33348993
Nat Med. 2020 Apr;26(4):458
pubmed: 32284617
Int Health. 2016 Sep;8(5):307-9
pubmed: 27620922
Health Soc Care Community. 2022 Sep;30(5):e2147-e2156
pubmed: 34791749
Nat Med. 2021 Jun;27(6):964-980
pubmed: 34002090
Risk Manag Healthc Policy. 2020 Aug 17;13:1187-1194
pubmed: 32904086
Int J Health Policy Manag. 2018 Feb 06;7(6):491-503
pubmed: 29935126
JMIR Public Health Surveill. 2021 Jun 18;7(6):e26267
pubmed: 33592576
Hum Vaccin Immunother. 2022 Dec 31;18(1):1975453
pubmed: 34674605
Int J Environ Res Public Health. 2021 Aug 27;18(17):
pubmed: 34501637
BMC Geriatr. 2021 Feb 5;21(1):102
pubmed: 33546612
Health Policy Plan. 2012 Oct;27 Suppl 4:iv4-8
pubmed: 23014152
Risk Manag Healthc Policy. 2021 Sep 24;14:3987-3992
pubmed: 34602826
Lancet Public Health. 2020 May;5(5):e251-e252
pubmed: 32199083
J Agromedicine. 2020 Oct;25(4):362-366
pubmed: 32921284
Lancet. 2020 Apr 18;395(10232):1243-1244
pubmed: 32305087
Confl Health. 2021 Apr 7;15(1):23
pubmed: 33827637
Iran J Public Health. 2021 Apr;50(4):806-815
pubmed: 34183931
Eur Heart J Qual Care Clin Outcomes. 2020 Jul 1;6(3):201-203
pubmed: 32374884
Int J Health Plann Manage. 2022 May;37(3):1229-1237
pubmed: 35146799
Front Public Health. 2021 Jun 18;9:671833
pubmed: 34222176
Int J Health Policy Manag. 2022 Oct 19;11(10):2155-2165
pubmed: 34814662
Ann Glob Health. 2020 Oct 08;86(1):133
pubmed: 33102153
Lancet. 2020 Aug 22;396(10250):519-521
pubmed: 32730743
Int J Equity Health. 2020 Jul 31;19(1):130
pubmed: 32736634
BMJ Glob Health. 2021 Jun;6(6):
pubmed: 34183330
BMC Health Serv Res. 2013 Apr 30;13:158
pubmed: 23631517
Lancet Glob Health. 2018 Nov;6(11):e1196-e1252
pubmed: 30196093
Lancet Reg Health Eur. 2021 Oct;9:100223
pubmed: 34642676
Health Policy. 2022 Jan;126(1):7-15
pubmed: 34857406
Nat Med. 2022 Jun;28(6):1314-1324
pubmed: 35288697
PLoS One. 2019 Sep 26;14(9):e0223104
pubmed: 31557243
Indian Econ Rev. 2020;55(Suppl 1):125-147
pubmed: 32836358
J Formos Med Assoc. 2020 Apr;119(4):884-885
pubmed: 32209276
BMJ. 2020 Oct 23;371:m4088
pubmed: 33097482
Lancet. 2020 Mar 14;395(10227):848-850
pubmed: 32151326
Disaster Med Public Health Prep. 2022 Feb;16(1):333-340
pubmed: 33004102
Lancet. 2021 Jan 2;397(10268):61-67
pubmed: 33275906
Soc Sci Med. 2017 Jan;172:89-97
pubmed: 27914936
Bull World Health Organ. 2022 Feb 01;100(2):161-167
pubmed: 35125541
J Epidemiol Community Health. 2020 Nov;74(11):964-968
pubmed: 32535550
Health Policy Plan. 2017 Nov 1;32(9):1337-1344
pubmed: 28981658
Lancet. 2020 Sep 26;396(10255):874
pubmed: 32979964

Auteurs

Dell D Saulnier (DD)

Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Anna Duchenko (A)

Swiss Tropical and Public Health Institute, Basel, Switzerland.

Sierra Ottilie-Kovelman (S)

Swiss Tropical and Public Health Institute, Basel, Switzerland.

Fabrizio Tediosi (F)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Karl Blanchet (K)

Geneva Centre of Humanitarian Studies, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH